Phase-Based Progress Estimates
University of California, San Diego, San Diego, CA
OPPEN - Behavioral
18 - 65
What conditions do you have?

Study Summary

This trial will test a program to train young Latino and Black men who have sex with men to promote PrEP use among HIV-negative YMSM of color in their social networks. The drug OPPEN is being used to treat HIV in this instance, and it should be noted that it has been approved by the FDA for a different condition in the past. It's important to mention that there is no placebo being used in this trial.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 6 Secondary · Reporting Duration: 3-month follow-up

3-month follow-up
PrEP linkage
PrEP uptake
PrEP behavioral skills
PrEP information
PrEP interest
PrEP motivation
Baseline and 3-month follow-up
OPPEN acceptability
OPPEN feasibility
PrEP conversations with peers

Trial Safety

Trial Design

1 Treatment Group

OPPEN Intervention
1 of 1
Experimental Treatment

210 Total Participants · 1 Treatment Group

Primary Treatment: OPPEN · No Placebo Group · N/A

OPPEN Intervention
Experimental Group · 1 Intervention: OPPEN · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3-month follow-up
Closest Location: University of California, San Diego · San Diego, CA
Photo of san diego 1Photo of san diego 2Photo of san diego 3
2022First Recorded Clinical Trial
0 TrialsResearching HIV
291 CompletedClinical Trials

Who is running the clinical trial?

University of California, San DiegoLead Sponsor
1,007 Previous Clinical Trials
1,792,954 Total Patients Enrolled
Heather A Pines, PhDPrincipal InvestigatorUniversity of California, San Diego

Eligibility Criteria

Age 18 - 65 · Male Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a cisgender male.
You are fluent in English.\n
You are a Latino or Black person.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.